Literature DB >> 10334560

Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy.

S Jerian, P Keegan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334560

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Cardiotoxic drugs in breast cancer.

Authors:  Alper Sevinc; Suleyman Buyukberber; Celalettin Camci
Journal:  J Natl Med Assoc       Date:  2004-05       Impact factor: 1.798

2.  A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy.

Authors:  Jeffrey E Cohen; Brendan P Purcell; John W MacArthur; Anbin Mu; Yasuhiro Shudo; Jay B Patel; Christopher M Brusalis; Alen Trubelja; Alexander S Fairman; Bryan B Edwards; Mollie S Davis; George Hung; William Hiesinger; Pavan Atluri; Kenneth B Margulies; Jason A Burdick; Y Joseph Woo
Journal:  Circ Heart Fail       Date:  2014-06-05       Impact factor: 8.790

Review 3.  Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.

Authors:  Nazish Sayed; Mohamed Ameen; Joseph C Wu
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

4.  Clinical trials and progress with paclitaxel in ovarian cancer.

Authors:  Sanjeev Kumar; Haider Mahdi; Christopher Bryant; Jay P Shah; Gunjal Garg; Adnan Munkarah
Journal:  Int J Womens Health       Date:  2010-11-19

5.  Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways.

Authors:  Thea Pugatsch; Suzan Abedat; Chaim Lotan; Ronen Beeri
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.